<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04294875</url>
  </required_header>
  <id_info>
    <org_study_id>JO201901-01</org_study_id>
    <nct_id>NCT04294875</nct_id>
  </id_info>
  <brief_title>Phase I, FIH, MTD for MPT0B640, Multi-centre, Open-label, Subject With Locally Advanced or Metastatic Solid Malignancies</brief_title>
  <acronym>MPT0B64</acronym>
  <official_title>Phase l, First in Human, Multi-centre, Open-label, Clinical Trial of MPT0B640 in Subject With Locally Advanced or Metastatic Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>J Ints Bio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>J Ints Bio</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase l, First in Human, Multi-centre, Open-label, Clinical Trial of MPT0B640 in Subject with&#xD;
      Locally Advanced or Metastatic Solid Malignancies&#xD;
&#xD;
      Phase I. Advanced or metastatic solid malignancy First in Human. HSP90 inhibitor Multi-center&#xD;
      clinical trials. Open label.&#xD;
&#xD;
      To determine the maximum tolerated dose (MTD) or maximum feasible dose (MFD) of MPT0B640&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Classical 3+3 design to determine the maximum tolerated dose (MTD) or maximum feasible dose&#xD;
      (MFD) of MPT0B640 .&#xD;
&#xD;
      Up to 9 times of administration, Oral suspension, once every 3rd day.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD of the dose of MPT0B640</measure>
    <time_frame>28days(+/-2days)</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <condition>Metastatic Solid Tumor</condition>
  <arm_group>
    <arm_group_label>MPT0B640</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>There is Single Arm in this Clinical Trials.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MPT0B640</intervention_name>
    <description>PO, every 3 days. dose escalation per MTD</description>
    <arm_group_label>MPT0B640</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Subjects must meet all inclusion criteria as listed below:&#xD;
&#xD;
          1. Histologically or cytologically confirmed, locally advanced or metastatic solid&#xD;
             malignancies, such as non-small cell lung cancer (NSCLC), breast cancer,&#xD;
             hepatocellular carcinoma, colorectal, prostate and pancreatic cancer who is not&#xD;
             suitable for surgery or radiotherapy.&#xD;
&#xD;
          2. Subjects who have progressed after receiving all available standard treatment known to&#xD;
             confer clinical benefit or for which no effective therapy exists.&#xD;
&#xD;
          3. Radiological documentation of disease progression while on a previous treatment.&#xD;
&#xD;
          4. Discontinued all previous treatment for cancer for at least 14 days and recovered from&#xD;
             the effects of therapy.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) 0 ~ 1&#xD;
&#xD;
          6. 19 years and older of age (Adult)&#xD;
&#xD;
          7. At least one measurable lesion by Response Evaluation Criteria in Solid Tumours&#xD;
             (RECIST 1.1)&#xD;
&#xD;
          8. Laboratory values: Hematologic parameters must be met without recent transfusions&#xD;
             within 7 days of enrolment.&#xD;
&#xD;
               1. Serum creatinine &lt; 1.5× upper limit of normal (ULN) or if higher than normal&#xD;
                  range, calculated creatinine clearance (CrCl) must be ≥ 60mL/min/1.73m2 (by&#xD;
                  Cockroft-Gault formula); actual body weight must be used for CrCl unless body&#xD;
                  mass index (BMI) &gt; 30kg/m2 then lean body weight must be used&#xD;
&#xD;
               2. Total bilirubin ≤ 1.5×ULN (except for Gilbert's syndrome which will allow&#xD;
                  bilirubin ≤2.0 ×ULN).&#xD;
&#xD;
               3. Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5×ULN, or ≤ 5×ULN&#xD;
                  if due to liver involvement by tumour.&#xD;
&#xD;
               4. Haemoglobin ≥ 9.0g/dL.&#xD;
&#xD;
               5. Platelets ≥ 100×109cells/L.&#xD;
&#xD;
               6. Absolute neutrophil count ≥ 1.5×109cells/L.&#xD;
&#xD;
          9. Subjects signed informed contents form&#xD;
&#xD;
         10. Expected lifespan ≥ 3 months&#xD;
&#xD;
         11. Female should be using adequate contraceptive measures, e.g., use at least two of the&#xD;
             following types of appropriate and effective birth control from 2 weeks prior to the&#xD;
             first dose of the study drug until 90 days after last dose. One of these methods must&#xD;
             be a double barrier method (condom with diaphragm plus spermicidal agent&#xD;
             [foam/gel/cream/film/suppository]). Additional methods are IUD or IUS, vasectomy by&#xD;
             sole male partner and use of approved oral, injected, or implanted hormonal methods of&#xD;
             contraception.&#xD;
&#xD;
         12. Female should not breast feeding and must have a negative pregnancy test prior to&#xD;
             start of dosing if of child-bearing potential or must have evidence of&#xD;
             non-child-bearing potential at screening.&#xD;
&#xD;
         13. Male subjects should be willing to use barrier contraception include using one of the&#xD;
             following during the study and for 90 days after last dose of the study drug.&#xD;
             (Abstinence, condom plus spermicidal agents [foam gel/cream/film/suppository])&#xD;
&#xD;
        Exclusion Criteria Any subject meeting one or more of the following exclusion criteria may&#xD;
        not be entered into the trial.&#xD;
&#xD;
          1. Symptomatic central nervous system (CNS) metastases which are neurologically unstable&#xD;
             or requiring increasing doses of steroids within the 28 days prior to study entry to&#xD;
             control their CNS disease and require local CNS-directed therapy&#xD;
&#xD;
          2. Systemic anticancer treatment 14 days prior to the first dose of study drug on Visit 1&#xD;
&#xD;
          3. Subjects who have undergone any major surgery* (as judged by the investigator,&#xD;
             excluding placement of vascular access) ≤ 28 days of the first dose of study drug on&#xD;
             Visit 1 or who have not recovered from side effects of such therapy&#xD;
&#xD;
             *Major surgery defined as a surgical operation within or upon the contents of the&#xD;
             abdominal, pelvic, cranial or thoracic cavities and a procedure which given the&#xD;
             locality, condition of patient, level of difficulty or length of time to perform,&#xD;
             constitutes a hazard to life or function of an organ or tissue. Major surgery usually&#xD;
             requires general anesthesia, a period of hospitalization of varying length (often a&#xD;
             week) and may be performed by a surgical subspecialist.&#xD;
&#xD;
          4. Limited-field radiotherapy ≤ 7 days or extended-field thoracic radiotherapy &lt; 28 days&#xD;
             of study drug on Visit 1&#xD;
&#xD;
          5. Subjects with&#xD;
&#xD;
               1. A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration&#xD;
                  of a QTc interval &gt; 480 milliseconds (ms) (CTCAE grade 1) using Frederica's QT&#xD;
                  correction formula.&#xD;
&#xD;
               2. A history of additional risk factors for TdP (e.g., heart failure, hypokalemia,&#xD;
                  family history of Long QT Syndrome).&#xD;
&#xD;
               3. The use of concomitant medications that prolong the QT/QTc interval.&#xD;
&#xD;
          6. Subjects with impaired cardiac function or clinically significant cardiac disease such&#xD;
             as:&#xD;
&#xD;
               1. Left ventricular ejection fraction &lt; 50%.&#xD;
&#xD;
               2. Clinically significant and/or uncontrolled heart disease such as congestive heart&#xD;
                  failure requiring treatment (NYHA Grade ≥ 2), uncontrolled hypertension, or&#xD;
                  clinically significant arrhythmia.&#xD;
&#xD;
               3. History of acute myocardial infarction or unstable angina pectoris &lt; 6 months&#xD;
                  prior to study entry.&#xD;
&#xD;
          7. Subjects who had a prior history of another malignancy over the last 5 years&#xD;
&#xD;
          8. Subjects able to swallow and retain orally administered medication and does not have&#xD;
             any clinically significant gastrointestinal abnormalities that may alter absorption&#xD;
             such as malabsorption syndrome or major restriction of the stomach or bowels&#xD;
&#xD;
          9. Subjects with active human immunodeficiency virus (HIV) or hepatitis B or C infection&#xD;
&#xD;
         10. Subjects who were administered another investigational product within 3 weeks prior to&#xD;
             screening&#xD;
&#xD;
         11. Subjects with any unresolved toxicity of Grade ≥ 2 from previous anti-cancer&#xD;
             treatment, except for alopecia and skin pigmentation.&#xD;
&#xD;
         12. Subjects with any clinically significant abnormal intestinal findings that may&#xD;
             interfere with the administration, passage, or absorption of the investigational&#xD;
             product, which makes the subjects unable to orally take the suspension form of drugs.&#xD;
&#xD;
         13. Subjects with drug abuse and unstable medical, psychological or social conditions that&#xD;
             may interfere with participating in the study or assessment of the results of the&#xD;
             study&#xD;
&#xD;
         14. Subjects with any condition or illness might compromise subject safety or interfere&#xD;
             with the evaluation of the safety of the drug by investigator's decision&#xD;
&#xD;
         15. Males and females of reproductive potential who are not using an effective method of&#xD;
             birth control and females who are pregnant or breastfeeding or have a positive (urine&#xD;
             or serum) pregnancy test prior to study entry&#xD;
&#xD;
         16. According to investigator's judgement, protocols cannot be followed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ethan Seah</last_name>
    <role>Study Director</role>
    <affiliation>J Ints Bio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiseon Park</last_name>
    <phone>82-10-8508-2740</phone>
    <email>ramona.park@jintsbio.com</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 2, 2020</study_first_submitted>
  <study_first_submitted_qc>March 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2020</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

